<DOC>
	<DOCNO>NCT02318407</DOCNO>
	<brief_summary>This sequential , randomize , double-blind , placebo control , multiple dose , dose escalation study subject OA knee pain ( n=32 ; 8/cohort ) . In cohort , subject randomize 3:1 receive SC AMG 403 placebo every 4 week total 4 dos ( Q28D x 4 ) .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics AMG 403 Subjects With Osteoarthritis Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Diagnosed knee OA determine ACR criterion : Knee pain radiographic osteophyte least 1 follow 2 item : Morning stiffness 30 minute , Crepitus motion , VAS pain score â‰¥ 30 mm index knee screening , Weight &gt; 125 kg , Inflammatory arthropathy include secondary OA ( eg , degenerative arthritis patient rheumatoid arthritis ) confirm rheumatologist investigator , Diagnosis condition knee OA , investigator 's opinion , may cause affect pain pain assessment index knee ; condition may include limited radiculopathy neuropathy , vasculopathy , fibromyalgia active depression , Subjects take neuromodulatory agent ( antiepileptic antidepressant ) use analgesic therapy neuropathic pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>